Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 2/2000

01.02.2000 | Disease Management

Schizophrenia in the Elderly

Guidelines for Management

verfasst von: Dr Martha Sajatovic, Subramoniam Madhusoodanan, Peter Buckley

Erschienen in: CNS Drugs | Ausgabe 2/2000

Einloggen, um Zugang zu erhalten

Abstract

The treatment of schizophrenia in older populations poses special challenges for patients, family members and clinicians. These include changes in manifestation of schizophrenic illness in later life, age-related changes in response to pharmacological treatments and psychosocial issues associated with older life status.
As with younger individuals, antipsychotic medications constitute the mainstay of treatment for schizophrenia in the elderly. However, the drug treatment of schizophrenia is substantially affected by the aging process. Medication sensitivity is pronounced in the elderly, largely due to age-related changes in the body’s capacity to metabolise psychotropic and other drugs. Other relevant factors include higher rates of physical comorbidity, drug-drug interactions and age-related adverse effects. Generally, the appropriate starting dose of antipsychotic medication in the elderly is 25% of the adult dose. Total daily maintenance doses may be 30 to 50% of the adult dose.
The use of conventional antipsychotics in the elderly is limited because of their association with extrapyramidal symptoms and anticholinergic and cardiovascular adverse effects. The advent of atypical antipsychotics has revolutionised the treatment of psychosis in the elderly. Based on the general psychiatric literature, the atypical agents have been found to be as efficacious as conventional agents in reducing positive symptoms, more efficacious against negative symptoms, and to have a much more benign adverse effect profile.
Nonpharmacological issues in the management of schizophrenia in the elderly are at least as important as in younger individuals. Older individuals may face additional challenges that affect health outcome, such as living alone or being unable to drive. All drug treatments should be partnered with supportive approaches and psychosocial interventions that maximise treatment compliance and improve outcome.
Literatur
1.
Malmgren R. Epidemiology of aging. In: Coffey CE, Cummings JL, editors. Textbook of geriatric neuropsychiatry. Washington, DC: American Psychiatric Press, 1994; 17–33
2.
Deamer RL, Thompson JF. The role of medications in geriatric sexual function. Clin Geriatr Med 1991; 7: 95–111PubMed
3.
Gurland BJ, Cross PS. Epidemiology of psychopathology in old age. Psychiatr Clin North Am 1982; 5: 11–26PubMed
4.
Ruskin PE. Schizophrenia and delusional disorders. Verwoerdt’s Clin Geropsychiatr 1990; 125–35
5.
Cohen CI. Outcome of schizophrenia into later life: an overview. Gerontologist 1990; 30: 790–7PubMedCrossRef
6.
Sajatovic M, Donenwirth K, Sultana D, et al. Age-related comparison of health resource utilization in women with serious mental illness [abstract]. Schizophr Res 1999; 36(1-3): 349
7.
Belisky R, McGlashan TH. The manifestations of schizophrenia in late life: a dearth of data. Schizophr Bull 1993; 19: 683–5CrossRef
8.
Davidson J, Harvey PD, Powchick P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 1995; 152: 2: 197–207
9.
Kraepelin E. Dementia Praecox. In: Kraepelin E, Diefendorf AR, translators. Clinical psychiatry: a textbook for studentsand physicians. 6th ed. New York (NY): Macmillan Press, 1902
10.
Jeste DJ. Late-life schizophrenia: editor’s introduction. SchizophrBull 1993; 19(4): 687–9CrossRef
11.
12.
Bleuler M. The schizophrenic disorders: long-term patient and family studies. New Haven (CT): Yale University Press, 1978
13.
Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 1980; 6: 606–18PubMedCrossRef
14.
Huber G, Gross G, Schuttler R, et al. Longitudinal studies of schizophrenia patients. Schizophr Bull 1980; 6(4) 592–605PubMedCrossRef
15.
Ciompi L. Review of follow-up studies on long-term evolution and aging in schizophrenia. In: Miller NE, Cohen GD, editors. Schizophrenia and aging. New York (NY): Guilford Press, 1987
16.
Tsuang M, Woolson R, Fleming J. Long-term, outcome of major psychosis. Schizophrenia and affective disorders compared with psychiatrically symptom free surgical conditions. Arch Gen Psychiatry 1979; 36: 1295–301
17.
Harding DM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness. I. Methodology, study sample and overall status 32 years later. Am J Psychiatry 1987; 144: 718–26
18.
McGlashan TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988; 14: 515–42PubMedCrossRef
19.
Pfohl B, Winokur G. The evolution of symptoms in institutionalized hebephrenic/catatonic schizophrenics. Br J Psychiatry 1982; 141: 567–72PubMedCrossRef
20.
Schulz SK, Miller DD, Oliver SE, et al. The life-course of schizophrenia: age and symptom dimensions. Schizophr Res 1997; 23: 15–23CrossRef
21.
Seeman M. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986: 73(6): 609–17PubMedCrossRef
22.
Riecher-Rossler A, Hafner H, Dutsch-Strobela A, et al. Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 1994; 36(7): 492–4PubMedCrossRef
23.
Powchik KP, Davidson M, Nemeroff CB, et al. Alzheimer-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry 1993; 150: 1726–7PubMed
24.
Haroutunian V, Davidson M, Kanof PD, et al. Cortical cholinergic markers in schizophrenia. Schizophr Res 1994; 12: 137–44PubMedCrossRef
25.
Heaton R, Paulsen JS, McAdams LA, et al. Neuropsychological deficits in schizophrenics. Arch Gen Psychiatry 1994; 51: 469–76PubMedCrossRef
26.
Addington J, Addington D. Positive and negative symptoms of schizophrenia: their course and relationship over time. Schizophr Res 1991; 5: 51–9PubMedCrossRef
27.
American Psychiatric Association. DSM-III. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
28.
American Psychiatric Association. DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
29.
American Psychiatric Association DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
30.
Tran-Johnson TK, Krull AJ, Jeste DV. Late-life schizophrenia and its treatment: pharmacologic issues in older schizophrenia patients. Clin GeriatrMed 1992; 8(2): 401–10
31.
World Health Organization. International classification of diseases. 10th rev. Geneva: World Health Organization, 1992
32.
Jeste DV, Harris MJ, Pearlson GD, et al. Late-onset schizophrenia: studying clinical validity. Psychiatr Clin North Am 1988; 11: 1–14PubMed
33.
Almeida OP, Howard RJ, Levy R, et al. Psychotic states arisingin late life (late paraphrenia). The role of risk factors. Br J Psychiatry 1995; 166: 215–28
34.
Devane CL. Principles of pharmacokinetics and pharmacodynamics. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press Inc., 1998
35.
von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Psychotropic drug metabolism in old age principles and problems of assessment. In: Bloom FE, David J, editors. Fourth generation of progress. New York (NY): Kupfer Raven Press Ltd, 1995
36.
Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081–8PubMedCrossRef
37.
38.
Gierz M, Jeste DV. Physical comorbidity in elderly veteransaffairs patients with schizophrenia and depression. Am J Geriatr Psychiatry 1993; 1(2): 165–70CrossRef
39.
Lazare A. Medical disorders in psychiatric populations, In: Lazare A, editor. Outpatientpsychiatry: diagnosis and treatment. Baltimore (MD): Williams and Wilkins, 1989; 240–5
40.
Jeste DV, Gladsjo JA, Lindamer LA, et al. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 413–30PubMedCrossRef
41.
Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophr Bull 1996; 22: 485–99PubMedCrossRef
42.
Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11–54PubMedCrossRef
43.
deLeon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiologic survey in a state hospital. Am J Psychiatry 1995; 152: 453–5
44.
Weickert-Shannon C, Kleinman JE. The neuroanatomy and neurochemistryof schizophrenia. Psychiatr Clin North Am 1998;21(1): 57–76CrossRef
45.
Targum SD, Abbott JL. Psychosis in the elderly: a spectrum of disorders. J Clin Psychiatry 1999; 60(8 Suppl.): 4–10PubMed
46.
Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctiveanticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9PubMedCrossRef
47.
Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, Ltd, 1995
48.
Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale and tardive dyskinesia study. Arch Gen Psychiatry 1993; 50: 723–33
49.
Hoffman WF, Ballard L, Turner EH, et al. Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biol Psychiatry 1991; 30(9): 913–26PubMedCrossRef
50.
Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6PubMedCrossRef
51.
Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52: 756–65PubMedCrossRef
52.
Woerner MG, Alvir JMJ, Saltz BL, et al, Prospective study of tardive dyskinesia in the elderly. Am J Psychiatry 1998; 155: 1521–8PubMed
53.
Jeste DV, Lacro JP, Palmer B. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 256: 309–11
54.
Waddington JL, Youssef HA. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dipkinesia. Psychol Med 1996; 26(4): 681–8PubMedCrossRef
55.
Jeste DV, Lacro JP, Gilbert PL, et al. Treatment of late-life schizophrenia with neuroleptics. SchizophrBull 1993; 19: 817–30CrossRef
56.
Owens DGC, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982; 39: 452–61PubMedCrossRef
57.
Brecher M. Follow up study of risperidone in the treatment of patients with dementia: interim results on tardive dyskinesia and dyskinesia severity [abstract no. NR 342]. In: Winstead DK, Skodol AE, Chairpersons. New research program and abstracts. American Psychiatric Association Annual Meeting: 1998 May 30–Jun 4; Toronto, Ontario. Washington, DC: American Psychiatric Association, 1998
58.
Kuntz AJ, Reams SG, Sanger TM, et al. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders. American Association of Geriatric Psychiatry Annual Meeting: 1998 Mar 9–11; San Diego
59.
Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10PubMedCrossRef
60.
Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapineinduced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162–7PubMedCrossRef
61.
Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatric Annals 1999; 29(10): 580–94
62.
Bandelow B, Fritze J, Ruther E. Increased mortality in schizophrenia and the possible influence of antipsychotic treatment. Int J Psych Clin Pract 1998; 2: S49–S57
63.
Barnes TRE, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999; 174: 34–43
64.
Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57–65PubMedCrossRef
65.
Taylor D, Lader M. Cytochromes and psychotropic drug interactions. Br J Psychiatry 1996; 168: 529–32PubMedCrossRef
66.
Buckley P, Larkin C, O’Callaghan E. Psychosis following useof proprietary antidiarrhoeal medicines. Br J Psychiatry 1990;157: 758–9PubMedCrossRef
67.
Centorrino R, Baldessarini RJ, Frankenburg FR. Serum levels of clozapine and nonclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153:820–2PubMed
68.
Fuller M, Sajatovic M. Drug information handbook for psychiatry.1st ed. Cleveland (OH): Lexi-Comp, Inc., 1999
69.
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(4 Suppl.): 1–63
70.
Raskind M, Elvarey C, Herlin RN. Fluphenazine enanthate in the treatment of late paraphrenia. J Am Geriatr Soc 1979; 27: 459–63PubMed
71.
Howard R, Levy R. Which factors affect treatment response in late paraphrenia? International response in late paraphrenia? Int J Geriatr Psychiatry 1992; 7: 667–72CrossRef
72.
McEvoy JP, Mccue M, Spring B, et al. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry 1987: 144: 573–7PubMed
73.
Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14(2): 87–96PubMedCrossRef
74.
Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 1996; 124(1-2): 57–73CrossRef
75.
Kumar V. Use of atypical agents in geriatric patients: a review. Int J Geriatr Psychopharmacology 1997; 1: 15–23
76.
77.
Physician’s desk reference. 53rd ed. Montvale (NJ): Medical Economics Company, 1999
78.
Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999; 60: 41–4PubMedCrossRef
79.
Chengappa KN, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychosis. J Geriatr Psychiatry Neurol 1995; 8: 12–5PubMed
80.
Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994; 7: 129–32PubMed
81.
Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavior disruption. Am J Geriatr Psychiatry 1995; 3: 26–33
82.
Sajatovic M, Jaskiw G, Konicki PE, et al. Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry 1997; 12: 553–8PubMedCrossRef
83.
Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56: 180–5PubMed
84.
Richards SS, Sweet RA, Ganguli R, et al. Clozapine: acute and maintenance treatment in late life psychosis [abstract]. Am J Geriatr Psychiatry 1996; 4: 377–8
85.
Sajatovic M, Ramirez LF, Garver D, et al. Clozapine therapy for older veterans. Psychiatric Services 1998; 49(3): 340–4PubMed
86.
Overall JE, Gorham D. The brief psychiatric rating scale. Psychologic Rep 1962; 10: 799–812CrossRef
87.
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact of risk-benefit assessment. Am J Psychiatry 1995; 152: 183–90PubMed
88.
Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998; 59(1 Suppl.): 5–10PubMed
89.
Abernathy DR. Psychotropic drugs and the aging process: pharmacokinetics and pharmacodynamics. In: Salzman C, editor. Clin Geriatr Psychopharmacol. 2nd ed. Baltimore (MD): Williams and Wilkins, 1992
90.
Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychosis associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514–8PubMed
91.
Sajatovic M, Ramirez LF, Vernon L, et al. Outcome of risperi done therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996; 26: 309–17PubMedCrossRef
92.
Zarate Jr CA, Baldessarini RJ, Seigel AT, et al. Risperidone in the elderly: a pharmaco-epidemiologic study. J Clin Psychiatry 1997; 58: 311–7PubMedCrossRef
93.
Madhusoodanan S, Suresh P, Brenner R, et al. Experience with the atypical antipsychotics—risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11(3): 113–8PubMed
94.
Reyntjens A, Heylen S, Gelders Y, et al. Risperidone in the treatment of behavioral symptoms in psychogeriatric patients: a pilot clinical investigation [abstract]. Psychopharmacology 1988; 96 Suppl. 1: 335
95.
Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57 Suppl. 3: 39–45
96.
Berman I, Merson A, Sison C, et al. Regional blood flow changes associated with risperidone treatment in elderly schizophrenic patients: a pilot study. Psychopharmacol Bull 1996; 32:95–100PubMed
97.
Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999; 7: 132–8PubMed
98.
Kay R, Fiszbein A, Opler I. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987; 13: 261–76CrossRef
99.
Chouinard G, Ross-Chouinard A, Annabel I, et al. The extrapyramidal symptoms rating scale [abstract]. Can J Neurol Sci 1980: 7: 233
100.
Berman I, Merson A, Allan F, et al. Effect of risperidone oncognitive performance in elderly schizophrenic patients: a double blind comparison study with haloperidol [abstract]. Psychopharmacol Bull 1995; 31: 552
101.
Jeste DV, Lacro JP, Nguyen HA, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47(6): 716–9PubMed
102.
Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients [abstract]. Psychopharmacol Bull 1995; 31: 534
103.
Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. In press
104.
Sajatovic M, Perez D, Brescan D, et al. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull 1998; 34(4): 819–23PubMed
105.
Berman I, Bayog RD, Wu C, et al. Cognitive effect of olanzapine [abstract no. NR 532]. In: Winstead DK, Skodol AE, Chairpersons. New research program and abstracts. American Psychiatric Association Annual Meeting: 1998 May 30–Jun 4; Toronto, Ontario. Washington, DC: American Psychiatric Association, 1998
106.
McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60: 292–8PubMedCrossRef
107.
Guy W. ECDEU assessment manual for psychopathology. Pub(ADM) 76-338. Rockville (MD): National Institute of Mental Health, 1976
108.
Seeger TE, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88, 059)a new antipsychotic with combined dopamine andserotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13PubMed
109.
Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. JSerotonin Res 1997; 4: 159–77
110.
Fein S. Treatment of drug refractory schizophrenia. Psychiatr Ann 1998; 28: 215–9
111.
Palmer BW, Heaton SC, Jeste DV. Older patients with schizophrenia:challenges in the coming decades. Psychiatr Serv 1999; 50(9): 1178–83PubMed
112.
Patterson TL, Jeste DV. The potential impact of the baby-boomgeneration on substance abuse among elderly persons. PsychiatrServ 199; 50(9): 1184-8
113.
Lehman AF. Public health policy, community services, and outcomesfor patients with schizophrenia. Psychiatr Clin NorthAm 1998; 21(1): 221–31CrossRef
114.
115.
Lamy PP, Salzman C, Nevis-Olesen J. Drug prescribing patterns, risks and compliance guidelines. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2. Baltimore (MD): Williams and Wilkins, 1992
Metadaten
Titel
Schizophrenia in the Elderly
Guidelines for Management
verfasst von
Dr Martha Sajatovic
Subramoniam Madhusoodanan
Peter Buckley
Publikationsdatum
01.02.2000
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 2/2000
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200013020-00004

Weitere Artikel der Ausgabe 2/2000

CNS Drugs 2/2000 Zur Ausgabe

Disease Management

Epidemiology and Treatment of Epilepsy in Patients who are Mentally Retarded

Leading Article

Adenosine as a Potential Analgesic Target in Inflammatory and Neuropathic Pains

Disease Management

Post-Traumatic Seizures

Review Article

Assessment of Agents for the Treatment of Head Injury

Leading Article

Helicobacter pylori Infection and Migraine

Leading Article

Histamine H1 Receptor Antagonists in the Treatment of Insomnia

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise